Antimalarial Drug Target Discovery in Plasmodium falciparum

Plasmodium falciparum remains the most lethal of the malaria-causing parasites, and the rise of resistance to front-line therapies has intensified the search for new molecular targets. Historically, drug discovery emphasised phenotypic screening of compound libraries, but the contemporary paradigm blends functional genomics, structural biology and chemoproteomics to reveal essential parasite proteins. Key efforts have focused on characterising enzymes of protein synthesis, redox metabolism, lipid biosynthesis and haem detoxification. Aminoacyl-tRNA synthetases have emerged as highly druggable targets, with selective inhibition of parasite variants achievable through structure-guided design. Enzymes of the apicoplast, a plastid-like organelle unique to apicomplexan parasites, also offer novel targets distinct from human pathways. Advances in high-throughput CRISPR screens and saturation mutagenesis platforms enable comprehensive mapping of essential genes and resistance-conferring mutations in defined binding pockets. These tools accelerate the transition from target identification to lead optimisation by highlighting liabilities such as rapid resistance emergence. Complementary approaches such as virtual screening and molecular dynamics refine pharmacophore models and predict favourable absorption, distribution, metabolism and excretion (ADME) properties. Collectively, these interdisciplinary strategies underpin a pipeline that integrates genetic validation, structural insight and chemical tractability to deliver the next generation of antimalarials.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antimalarial Drug Target Discovery in Plasmodium falciparum publication trend

The graph below shows the total number of articles in antimalarial drug target discovery in plasmodium falciparum across all publications each year (not limited to Nature Index journals).

Technical terms

Aminoacyl-tRNA synthetase (aaRS): An enzyme that attaches amino acids to their corresponding transfer RNAs during protein synthesis.

Phenotypic screening: A method that tests compounds on whole organisms or cells to identify those causing a desired biological effect without prior knowledge of the target.

Structure-guided drug design: The process of designing molecules based on the three-dimensional structure of a target protein.

Saturation mutagenesis: A technique that generates all possible amino acid substitutions at defined positions to map functional or resistance-conferring variants.

Pharmacophore: An abstract representation of molecular features necessary for optimal interactions with a target protein.

Apicoplast: A non-photosynthetic plastid organelle in apicomplexan parasites, derived from algae, essential for specific metabolic pathways.

References

1. Targeting Aminoacyl tRNA Synthetases for Antimalarial Drug Development. Annual Review of Microbiology (2023).
2. ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium. mBio (2024).
3. Structure-Based Design and Pharmacophore-Based Virtual Screening of Combinatorial Library of Triclosan Analogues Active against Enoyl-Acyl Carrier Protein Reductase of Plasmodium falciparum with Favourable ADME Profiles. International Journal of Molecular Sciences (2023).